|
| Press Releases |
|
 |
|
| Saturday, August 24, 2024 |
|
|
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1 |
| Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1. more info >> |
|
| Tuesday, March 26, 2024 |
|
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine |
| Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. more info >> |
|
| Monday, December 11, 2023 |
|
|
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event |
| more info >> |
|
| Wednesday, July 5, 2023 |
|
|
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 |
| Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. more info >> |
|
| Wednesday, May 3, 2023 |
|
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
| Tuesday, September 13, 2022 |
|
|
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines |
| PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
| Friday, September 9, 2022 |
|
|
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines |
| PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in the manufacturing process of IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
| Tuesday, July 19, 2022 |
|
|
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 ug per dose for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to 5 years. more info >> |
|
| Thursday, February 17, 2022 |
|
|
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years) |
| Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has granted provisional registration for the use of Moderna's mRNA COVID-19 vaccine, Spikevax, in a 50 ug dose, two-dose series, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years. more info >> |
|
| Wednesday, February 16, 2022 |
|
|
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries |
| Moderna, Inc., (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to expand its commercial network across Asia with the addition of four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong. This expansion comes as the Company continues to scale up the manufacturing and distribution of its COVID-19 vaccine and future mRNA vaccines and therapeutics. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals 
Dec 15, 2025 23:00 JST
|
|
|
GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes
Dec 15, 2025 21:09 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
Dec 15, 2025 21:00 HKT/SGT
|
|
|
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
Dec 15, 2025 19:41 JST
|
|
|
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
Dec 15, 2025 19:04 JST
|
|
|
Everest Medicines Unveils 2030 Strategy as Directors and Substantial Shareholder Buy Over HKD 38 Million of Shares
Dec 15, 2025 16:59 HKT/SGT
|
|
|
Indonesia's KAI Launches Farmer-Trader Train, Expands Facial Recognition Tech Ahead of 2025/2026 Holiday Travel Surge
Dec 15, 2025 13:00 HKT/SGT
|
|
|
TransNusa Secures 19 Scheduled Flight Routes Within Three Years of Operations
Dec 15, 2025 09:51 HKT/SGT
|
|
|
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 8:30 JST
|
|
|
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
|
|
|
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Dec 12, 2025 14:35 HKT/SGT
|
|
|
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Dec 12, 2025 11:00 JST
|
|
|
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Dec 11, 2025 20:00 HKT/SGT
|
|
|
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing
Dec 11, 2025 18:09 HKT/SGT
|
|
|
Nasdaq Verafin Joins Global Anti-Scam Alliance
Dec 11, 2025 14:21 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
